Company: MDCXW
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001062993-25-008292
Chunk: 155

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-01
Form: DRS
Chunk 155
---
4. In December 2024, reimbursable salaries were changed to $100,000 per month.

<div align='center'>- 103 -</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

(2)Dr. Edward Brennan served as our Chief Medical Officer from September 2023 to November 2024. Dr. Edward Brennan has served as our Chief Scientific Officer & Head of R&D Program since November 2024.

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth certain information concerning equity awards granted to our named executive officers that remained outstanding as of December 31, 2024.

| Name               |    Number of Securities 
  Underlying Unexercised 
 Options Exercisable (#) |   Number of Securities 
 Underlying Unexercised 
  Options Unexercisable 
                 (#)(1) | Option Exercise Price 
                  (C$) | Option          
 Expiration Date |
| Dr. Raza Bokhari   |                 250,000 |                      - |                  1.16 | 10/24/2028      |
|                    |                       - |                 50,000 |                  3.95 | 12/17/2029      |
| James Quinlan      |                 125,000 |                      - |                  1.16 | 10/24/2028      |
|                    |                       - |                 20,000 |                  3.95 | 12/17/2029      |
| Dr. Edward Brennan |                  75,000 |                      - |                  1.16 | 10/24/2028      |
|                    |                       - |                 20,000 |                  3.95 | 12/17/2029      |

(1)The options are scheduled to vest quarterly in four equal installments over one year from the grant date of December 17, 2024.

Employment and Consulting Agreements with Executive Officers

We have entered into written employment agreements with James Quinlan, our Chief Financial Officer, Edward Brennan, our Chief Scientific Officer and Faisal Mehmud, our Chief Medical Officer. Such agreements provide for a base salary, an annual discretionary bonus, notice and payment requirements upon termination without cause or as a result of a change in control, and payments following or in connection